PART I . Overview We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (HSV-1), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cells own machinery then transcri...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001711279-26-000016 | EDGAR | 86K words |
| 2025-02-19 | 2024-12-31 | 0001711279-25-000008 | EDGAR | — |
| 2024-02-26 | 2023-12-31 | 0001711279-24-000005 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001711279-23-000008 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001711279-22-000004 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001711279-21-000006 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001564590-20-009550 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001564590-19-007267 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005252 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-03 | 2025-09-30 | 0001711279-25-000087 | EDGAR | 19K words |
| 2025-08-04 | 2025-06-30 | 0001711279-25-000077 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001711279-25-000044 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0001711279-24-000056 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001711279-24-000040 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001711279-24-000020 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001711279-23-000073 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001711279-23-000064 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001711279-23-000029 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001711279-22-000058 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001711279-22-000047 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001711279-22-000016 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-17 | 0001711279-26-000018 | EDGAR | 4K words |
| 2026-01-12 | 0001711279-26-000008 | EDGAR | — |
| 2026-01-08 | 0001711279-26-000005 | EDGAR | — |
| 2025-12-23 | 0001711279-25-000092 | EDGAR | — |
| 2025-11-03 | 0001711279-25-000088 | EDGAR | — |
| 2025-10-22 | 0001711279-25-000082 | EDGAR | — |
| 2025-08-04 | 0001711279-25-000078 | EDGAR | — |
| 2025-07-25 | 0001711279-25-000071 | EDGAR | — |
| 2025-07-24 | 0001711279-25-000069 | EDGAR | — |
| 2025-07-09 | 0001711279-25-000065 | EDGAR | — |
164 total filings indexed. 133 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001711279 |
| Ticker | KRYS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.krystalbio.com |
| Listed | 2017-09-20 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report